Skip to content
lsd.com
Not yet recruitingPhase 1

The Effects of Psilocybin on Social Connectedness

NCT07693153 · Yale University

Closed to entry
Status
Not accepting participants
Phase 1
Phase
51
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional stimuli during the Facial Emotion Recognition Task (FERT) compared to a placebo in adults who feel lonely or those with unresolved grief symptoms.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Loneliness and social connectedness

    Measured over Baseline (Day -1) and Day +7, Day +30

  • fMRI Baseline Assessments

    Measured over Day -2, Day +7

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

21 Years to 65 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * Medically healthy * Ability to provide consent * High loneliness defined by the UCLA-3 Loneliness Scale * Willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: * Any unstable medical condition, psychiatric disorder, or circumstance that, in the opinion of the investigator, could compromise participant safety, interfere with study participation, or hinder the participant's ability to comply with study procedures and requirements * Positive pregnancy test or women who are breastfeeding * Any contraindication to MRI such as a pacemaker or metal implants

Where

1 study site

FacilityCityRegionCountry
Connecticut Mental Health CenterNew HavenConnecticutUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07693153 on ClinicalTrials.gov →

Last updated in the registry 2026-07-09. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Indication

Recruiting in

All 49 trials from Yale University →